aptevo therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. we leverage the innovative adaptir™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. based in seattle, washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. as a result, aptevo has been able to attract some of the most innovative minds in the field. many of our team members have notable experience with other pioneering biotech companies including trubion, zymogenetics, immunex, dendreon, and vlst. at aptevo therapeutics, our core values of ownership and collaboration—combined with a history of innovation, dedication, and development—are positioning aptevo therapeutics to develop the science of what’s next in biotechnology.
Company profile
Ticker
APVO, APVTW
Exchange
Website
CEO
Marvin L. White
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Aptevo Research and Development LLC ...
APVO stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
1 Dec 23
S-3
Shelf registration
22 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
14 Nov 23
8-K
Entry into a Material Definitive Agreement
9 Nov 23
8-K
Entry into a Material Definitive Agreement
3 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Sep 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
10 Aug 23
8-K
Entry into a Material Definitive Agreement
4 Aug 23
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 19.11 mm | 19.11 mm | 19.11 mm | 19.11 mm | 19.11 mm | 19.11 mm |
| Cash burn (monthly) | 632.00 k | 288.92 k | 2.19 mm | 2.51 mm | 2.08 mm | 1.03 mm |
| Cash used (since last report) | 1.36 mm | 620.23 k | 4.69 mm | 5.40 mm | 4.47 mm | 2.22 mm |
| Cash remaining | 17.75 mm | 18.49 mm | 14.42 mm | 13.71 mm | 14.64 mm | 16.89 mm |
| Runway (months of cash) | 28.1 | 64.0 | 6.6 | 5.5 | 7.0 | 16.3 |
Institutional ownership, Q2 2023
6.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 23 |
| Opened positions | 3 |
| Closed positions | 4 |
| Increased positions | 3 |
| Reduced positions | 1 |
| 13F shares | Current |
|---|---|
| Total value | 1.18 bn |
| Total shares | 1.05 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Cantor Fitzgerald, L. P. | 251.12 k | $366.64 mm |
| Vanguard | 228.82 k | $334.08 mm |
| Schonfeld Strategic Advisors | 144.60 k | $211.12 mm |
| Hirschman Orin | 122.17 k | $5.08 mm |
| Renaissance Technologies | 80.19 k | $117.00 k |
| Geode Capital Management | 52.83 k | $77.12 mm |
| BLK Blackrock | 48.05 k | $70.15 mm |
| T. Rowe Price | 46.20 k | $68.00 k |
| NTRS Northern Trust | 17.64 k | $25.76 mm |
| Citadel Advisors | 12.78 k | $18.66 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 9 Aug 23 | Abdun-Nabi Daniel | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,571 | 0.00 | 8,339 |
| 9 Aug 23 | Abdun-Nabi Daniel | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 3,571 | 0.00 | 0 |
| 9 Aug 23 | Grady Grant III | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,571 | 0.00 | 4,880 |
| 9 Aug 23 | Grady Grant III | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 3,571 | 0.00 | 0 |
| 9 Aug 23 | Harsanyi Zsolt | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,571 | 0.00 | 8,475 |
| 9 Aug 23 | Harsanyi Zsolt | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 3,571 | 0.00 | 0 |
| 9 Aug 23 | Kunz Barbara Lopez | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,571 | 0.00 | 4,880 |
| 9 Aug 23 | Kunz Barbara Lopez | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 3,571 | 0.00 | 0 |
| 9 Aug 23 | Niederhuber John | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,571 | 0.00 | 5,682 |
| 9 Aug 23 | Niederhuber John | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 3,571 | 0.00 | 0 |
News
Aptevo Therapeutics: Q3 Earnings Insights
14 Nov 23
Aptevo Therapeutics Q3 EPS $(0.50) Beats $(0.75) Estimate; Aptevo Closed A Public Offering For $5M And Raised An Additional $2M Through The Exercise Of Warrants In November 2023, The Funding Extends The Cash Runway For At Least The Next Twelve Months
14 Nov 23
Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
10 Nov 23
Why Direct Digital Shares Are Trading Higher By Around 33%; Here Are 20 Stocks Moving Premarket
10 Nov 23
12 Health Care Stocks Moving In Friday's Pre-Market Session
10 Nov 23